A review of remdesivir for COVID-19 in pregnancy and lactation.
Sarah C J JorgensenMatthew R DavisStephen E LapinskyPublished in: The Journal of antimicrobial chemotherapy (2021)
Mounting evidence suggests that pregnant people have an elevated risk of severe COVID-19-related complications compared with their non-pregnant counterparts, underscoring the need for effective prevention and treatment strategies. However, despite progress in innovative and flexible trial designs during the COVID-19 pandemic, regressive policies excluding pregnant and breastfeeding people from biomedical research persist. Remdesivir, a broad-spectrum antiviral, was the first drug licensed for the treatment of COVID-19, based on data showing it reduced the time to recovery in hospitalized patients. Pregnant and breastfeeding people were specifically excluded from all clinical trials of remdesivir in COVID-19, but data are accumulating from post-marketing registries, compassionate use programmes and case series/reports. In this review we synthesize these data and highlight key knowledge gaps to help inform clinical decision-making about its use in pregnancy and lactation.
Keyphrases
- coronavirus disease
- sars cov
- clinical trial
- pregnant women
- electronic health record
- decision making
- preterm infants
- big data
- respiratory syndrome coronavirus
- human milk
- healthcare
- public health
- emergency department
- preterm birth
- phase ii
- phase iii
- risk factors
- dairy cows
- data analysis
- machine learning
- early onset
- low birth weight